Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYSTIC first-line NSCLC trial
NL-OMON44879Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Started Oct 2015; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44879.